The estimated Net Worth of Fred B Jr Davenport is at least $812 ezer dollars as of 17 February 2022. Mr. Davenport owns over 500 units of Medpace Inc stock worth over $669,140 and over the last 6 years he sold MEDP stock worth over $0. In addition, he makes $142,604 as Lead Independent Director at Medpace Inc.
Fred has made over 1 trades of the Medpace Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently he bought 500 units of MEDP stock worth $72,900 on 17 February 2022.
The largest trade he's ever made was buying 500 units of Medpace Inc stock on 17 February 2022 worth over $72,900. On average, Fred trades about 63 units every 0 days since 2018. As of 17 February 2022 he still owns at least 2,000 units of Medpace Inc stock.
You can see the complete history of Mr. Davenport stock trades at the bottom of the page.
Fred B. Davenport Jr. serves as Lead Independent Director of the Company. Mr. Davenport is a partner at the law firm of Murchison, Taylor & Gibson, PLLC and focuses his practice on mergers and acquisitions, general corporate representation and estate planning. He previously served as President of Pharmaceutical Product Development, Inc. ("PPD") from 2002 to 2006. From 2001 to 2002, Mr. Davenport was Executive Vice President of PPD and from 1996 to 2001 he was General Counsel of PPD. Prior to joining PPD, Mr. Davenport practiced at Murchison, Taylor & Gibson, PLLC as an associate from 1977 to 1980 and as a partner from 1981 to 1996, which included acting as the managing partner from 1991 to 1995. Mr. Davenport has also served on the faculty of the Cameron School of Business as a tenured professor. From 2015 to March 2016, Mr. Davenport was a Director of Clinipace Worldwide and from 2009 to 2011 he was a Director of Medex Global Group, Inc. Additionally, Mr. Davenport was a Director of predecessor entities of the Company from 2007 to 2013. Mr. Davenport has also served on numerous community and non-profit boards. Mr. Davenport received his Bachelor's Degree, MBA and JD from the University of North Carolina at Chapel Hill. Mr. Davenport was chosen as a director because of his significant experience in the CRO industry, his experience as an executive and his experience serving on boards.
As the Lead Independent Director of Medpace Inc, the total compensation of Fred Davenport at Medpace Inc is $142,604. There are 10 executives at Medpace Inc getting paid more, with August Troendle having the highest compensation of $7,712,840.
Fred Davenport is 68, he's been the Lead Independent Director of Medpace Inc since 2018. There are no older and 14 younger executives at Medpace Inc.
Fred's mailing address filed with the SEC is C/O MEDPACE HOLDINGS, INC., 5375 MEDPACE WAY, CINCINNATI, OH, 45227.
Over the last 8 years, insiders at Medpace Inc have traded over $3,140,136,825 worth of Medpace Inc stock and bought 2,899,276 units worth $330,034,155 . The most active insiders traders include Limited Partnership Medpace..., August J. Troendle és Investors, Llc Medpace. On average, Medpace Inc executives and independent directors trade stock every 9 days with the average trade being worth of $40,224,347. The most recent stock trade was executed by Robert O. Kraft on 22 August 2024, trading 8,127 units of MEDP stock currently worth $346,373.
a therapeutically focused leader in research-based drug development, medpace builds strong strategic partnerships with select sponsors to advance the most efficient and cost-effective path to drug approval. as a full service, global clinical research organization (cro), medpace sees itself as a steward of your drug, leveraging its extensive medical and regulatory expertise to deliver additional input, strategy, and efficiencies to each and every phase of the clinical trial. from custom solutions addressing the needs of small and midsize biotechnology companies to full-service offerings for global pharmaceutical companies, medpace has the breadth, depth, and flexibility to deliver a superior result, specific to your needs, on six continents.
Medpace Inc executives and other stock owners filed with the SEC include: